2009-10-07 14:16
Many a seasoned and sophisticated biopharma executive have described to me the reality of when an entity does not need to raise capital it should because at some point it will be needed, and… Read More
Blog Directory > Finance Blogs > Colorado Life Science Deal Flow finance Blog >
Colorado Life Science Deal Flow Blog
rnaventures.blogspot.com
Tags:
earlystage
life science
market
breast cancer awareness
cash
financings
nyse
dengue
july
life science investor
All about biotech and pharma drug development
2009-10-07 13:24
Inviragen (Ft. Collins, CO) a preclinical-stage vaccine company focused on emerging global infectious diseases, closed a $15M Series A financing and in the process merged the assets of Singa… Read More
2009-10-07 13:24
2009-10-06 14:55
[Update | Add Domain Associates, Domain Partners, VIII $500M to the early-stage drug and device sectors; bringing recently closed funds up to $1,925M]Recently Boston, MA-based Excel Venture… Read More
2009-10-06 14:16
GlobeImmune (Louisville, CO) a clinical-stage company focused on developing targeted immunogens for the treatment of cancer and infectious diseases, has had an abstract (“GI-5005 Thera… Read More
2009-10-06 13:54
Biodesix (Broomfiled, CO) a commercial-stage molecular diagnostics company focused on proteomic-based diagnostics, closed the first tranche of a $10M Series B financing. The company is enabl… Read More
2009-10-04 18:28
In recognition of October as Breast Cancer Awareness Month [C]LSDF is highlighting a few of the early-stage entities who are on the front-line in the battle against breast cancer that have b… Read More
2009-10-02 03:15
Part of the [C]LSDF ongoing series Watching the Bio IPO Market.Talecris Biotherapeutics (NASDAQ: TLCR) made a thunderous debut with its Initial Public Offering on the Nasdaq today, offering… Read More
2009-10-02 03:15
The Rocky Mountain Life Science Investor Conference yielded a sense of sophistication and intensity catalyzed by the aggregation of high-quality presenting companies and top-tier venture and… Read More
2009-09-29 03:04
Hot off the press! (and, better late than never…) The July 2009 OnBioVC | Trend Analysis study is now available for FREE via download [HERE]. Over $668M flowed into early-stage biopha… Read More
2009-09-28 04:40
Now, some 48-hours later, it may be considered old news that Allos Therapeutics (NASDAQ: ALTH) received from FDA accelerated approval for Folotyn™ (pralatrexate) for the treatment of p… Read More
2009-09-25 05:37
Today’s third of four installments covering the Rocky Mountain Life Science Investor Conference focuses on the medical device presenting companies. In addition, here are some links to… Read More
2009-09-23 23:20
Commercial-stage Snoasis Medical (Denver, CO) is focused on the development and commercialization of products which redefine the way clinicians perform perioplastic surgery. The core technol… Read More
2009-09-23 05:54
CLSDF continues to maintain keen watch on the thawing of the public equity markets, calibrated in a semi-quantitative approach via the life science IPO pricings. If all three of the current… Read More
2009-09-22 03:06
Continuing here with Part Deux of the Rocky Mountain Life Science Investor Conference presenting companies. Yesterday CLSDF posted the Diagnostic oriented entities, today we feature the biop… Read More
2009-09-22 02:55
Now this is interesting! The Food and Drug Administration's Center for Drug Evaluation and Research, in collaboration with FDA's Center for Biologics Evaluation and Research, Center for Vete… Read More
2009-09-21 03:42
I had the best intentions of bringing up to the minute information flowing through CLSDF from the content rich Rocky Mountain Life Science Investor Conference however, during the first compa… Read More
2009-09-21 01:31
EJ BioMed, a spin-off from Ft. Collins, CO-based Eldon James Corporation, who focuses on production of critical use components for medical devices, recently announced an exclusive supplier d… Read More
2009-09-17 16:18
UPDATE (Breakfast) - Roy Davis, VP Corporate Development at Johnson & Johnson (NYSE: JNJ) and President JNJ Development Corporation opened the first full day of the RMLIC. He focused on… Read More
2009-09-17 02:34
UPDATE: Lots can happen between an early morning blog post and the end of the business day. In this case Omeros has set its IPO terms; 6.82M common shares offered between $10 and $12 per s… Read More
2009-09-15 14:47
Recall that Steven Dow, DVM, Ph.D., Professor in the departments of Clinical Sciences and Pathology in the College of Veterinary Medicine at Colorado State University, co-founded Juvaris Bio… Read More
2009-09-14 05:32
There are a couple of upcoming seminars that are architected to yield some sophisticated insight on typically complex issues around financing early-stage life science companies. The first e… Read More
2006-06-07 11:16
This is the final post for Colorado Life Science Deal Flow (http://rnaventures.blogspot.com). We have packed up and moved to the new and improved Life Science Deal Flow site (http://LifeScie… Read More
2006-06-07 11:16
Good morning. Please note blog coverage this week of 12 October will be spotty as a result of new changes being implemented, particularly:1) The evolution of [Colorado] Life Science Deal Flo… Read More
2006-06-07 11:16
Omeros (NASDAQ: OMER) launched itself onto the Nasdaq global marketplace yesterday with its initial public offering of 6.82M shrs priced at $10 raising approximately $68M less underwriting e… Read More
2006-06-07 11:16
AGA Medical (Plymouth, MN) developer of interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders, first filed with the intent… Read More
Subscribe to Colorado Life Science Deal Flow
Get updates delivered right to your inbox!